8 minutes | Aug 10, 2020

Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies

Rick Greene, MD and Giorgos Karakousis, MD discuss the impact of immune checkpoint and BRAF/MEK pathway inhibitors on outcomes and melanoma care at a national population level in patients diagnosed with clinical stage III melanoma. Dr. Karakousis is author of, “Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.” Dr. Karakousis is Associate Professor of Surgery at the Hospital of the University of Pennsylvania, Philadelphia, PA.
Play
Like
Play Next
Mark
Played
Share